Meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine: a new conjugate vaccine against invasive meningococcal disease

References

• BrouwerMCTunkelARvan de BeekDEpidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitisClin Microbiol Rev201023346749220610819
   PubMed Web of Science ®Google Scholar
• BaltimoreRSRecent trends in meningococcal epidemiology and current vaccine recommendationsCurr Opin Pediatr200618586316470164
   PubMed Web of Science ®Google Scholar
• PollardAJGlobal epidemiology of meningococcal disease and vaccine efficacyPediatr Infect Dis J200423Suppl 12S274S27915597069
   PubMedGoogle Scholar
• NadelSProspects for eradication of meningococcal diseaseArch Dis Child2012971199399822984187
   PubMed Web of Science ®Google Scholar
• CohnACMacNeilJRClarkTAPrevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP)MMWR Recomm Rep201362RR–212823515099
   PubMed Web of Science ®Google Scholar
• TzengYLStephensDSEpidemiology and pathogenesis of Neisseria meningitidisMicrobes Infect20002668770010884620
   PubMed Web of Science ®Google Scholar
• de SouzaALvan de BeekDScheldWMMeningococcal DiseaseGuerrantRLWalkerDHWellerPFTropical Infectious Diseases: Principles, Pathogens and Practice3rd edEdinburghW.B. Saunders2011174183
   Google Scholar
• StephensDSGreenwoodBBrandtzaegPEpidemic meningitis, meningococcaemia, and Neisseria meningitidisLancet200736995802196221017604802
   PubMed Web of Science ®Google Scholar
• RouphaelNGStephensDSNeisseria meningitidis: biology, microbiology, and epidemiologyMethods Mol Biol201279912021993636
   PubMedGoogle Scholar
• GranoffDMPeltonSHarrisonLHMeningococcal vaccinesPlotkinSAOrensteinWAOffitPAVaccines6th edLondonW.B. Saunders2013388418
   Google Scholar
• ChristensenHMayMBowenLHickmanMTrotterCLMeningococcal carriage by age: a systematic review and meta-analysisLancet Infect Dis20101085386121075057
   PubMed Web of Science ®Google Scholar
• RosensteinNEPerkinsBAStephensDSPopovicTHughesJMMeningococcal diseaseN Engl J Med2001344181378138811333996
   PubMed Web of Science ®Google Scholar
• HarrisonLHProspects for vaccine prevention of meningococcal infectionClin Microbiol Rev200619114216416418528
   PubMed Web of Science ®Google Scholar
• KeiserPBBroderickMMeningococcal polysaccharide vaccine failure in a patient with C7 deficiency and a decreased anti-capsular antibody responseHum Vaccin Immunother20128558258622634438
   PubMed Web of Science ®Google Scholar
• CaugantDATzanakakiGKrizPLessons from meningococcal carriage studiesFEMS Microbiol Rev2007311526317233635
   PubMed Web of Science ®Google Scholar
• PapaevangelouVSpyridisNMenACWY-TT vaccine for active immunization against invasive meningococcal diseaseExpert Rev Vaccines201211552353722827239
   PubMed Web of Science ®Google Scholar
• GoldschneiderIGotschlichECArtensteinMSHuman immunity to the meningococcus. II. Development of natural immunityJ Exp Med19691296132713484977281
   PubMed Web of Science ®Google Scholar
• TanLKCarloneGMBorrowRAdvances in the development of vaccines against Neisseria meningitidisN Engl J Med2010362161511152020410516
   PubMed Web of Science ®Google Scholar
• D’AgatiVCMarangoniBAThe Waterhouse-Friderichsen SyndromeN Engl J Med1945232117
   Web of Science ®Google Scholar
• FellickJMSillsJAMarzoukOHartCACookeRWThomsonAPNeurodevelopmental outcome in meningococcal disease: a case-control studyArch Dis Child200185161111420186
   PubMed Web of Science ®Google Scholar
• PaceDPollardAJMeningococcal disease: clinical presentation and sequelaeVaccine201230Suppl 2B3B922607896
   PubMed Web of Science ®Google Scholar
• EricksonLJDe WalsPMcMahonJHeimSComplications of meningococcal disease in college studentsClin Infect Dis200133573773911477523
   PubMed Web of Science ®Google Scholar
• KimmelSRPrevention of Meningococcal DiseaseAm Fam Physician2005722049205616342836
   PubMed Web of Science ®Google Scholar
• GardnerPClinical practice. Prevention of meningococcal diseaseN Engl J Med2006355141466147317021322
   PubMed Web of Science ®Google Scholar
• HebertCJHallCMOdomsLNLessons learned and applied: what the 20th century vaccine experience can teach us about vaccines in the 21st centuryHum Vaccin Immunother20128556056822617834
   PubMed Web of Science ®Google Scholar
• JódarLFeaversIMSalisburyDGranoffDMDevelopment of vaccines against meningococcal diseaseLancet200235993161499150811988262
   PubMed Web of Science ®Google Scholar
• RamsayMKaczmarskiERushMMallardRFarringtonPWhiteJChanging patterns of case ascertainment and trends in meningococcal disease in England and WalesCommun Dis Rep CDR Rev199774R49R549127510
   PubMedGoogle Scholar
• RouphaelNGZimmerSMStephensDSNeisseria meningitidisBarrettADTStanberryLRVaccines for Biodefense and Emerging and Neglected DiseasesLondonAcademic Press200910611079
   Google Scholar
• No authors listedMeningococcal disease in countries of the African meningitis belt, 2012 – emerging needs and future perspectivesWkly Epidemiol Rec20138812129136 English, French23544241
   PubMedGoogle Scholar
• HarrisonLHTrotterCLRamsayMEGlobal epidemiology of meningococcal diseaseVaccine200927Suppl 2B51B6319477562
   PubMed Web of Science ®Google Scholar
• PolandGAPrevention of meningococcal disease: current use of polysaccharide and conjugate vaccinesClin Infect Dis201050Suppl 2S45S5320144016
   PubMed Web of Science ®Google Scholar
• LingappaJRAl-RabeahAMHajjehRSerogroup W-135 meningococcal disease during the Hajj, 2000Emerg Infect Dis20039666567112781005
   PubMed Web of Science ®Google Scholar
• BorrowRMeningococcal disease and prevention at the HajjTravel Med Infect Dis20097421922519717104
   PubMed Web of Science ®Google Scholar
• MemishZAVenkateshSAhmedQATravel epidemiology: the Saudi perspectiveInt J Antimicrob Agents20032129610112615370
   PubMed Web of Science ®Google Scholar
• Ongoing Struggle with Meningitis W135 in Chile Available from: http://healthmap.org/site/diseasedaily/article/ongoing-struggle-meningitis-w135-chile-61813Accessed June 15, 2013
   Google Scholar
• BoisierPNicolasPDjiboSMeningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in NigerClin Infect Dis200744565766317278055
   PubMed Web of Science ®Google Scholar
• SewardRJTownerKJEvaluation of a PCR-immunoassay technique for detection of Neisseria meningitidis in cerebrospinal fluid and peripheral bloodJ Med Microbiol200049545145610798558
   PubMed Web of Science ®Google Scholar
• MacNeilJRChapter 8: Meningococcal Disease; Manual for the Surveillance of Vaccine-Preventable Diseases (5th Edition, 2011) [webpage on the Internet]AtlantaCenters for Disease Control and Prevention2011 Available from: http://www.cdc.gov/vaccines/pubs/surv-manual/chpt08-mening.html
   Google Scholar
• JoshiVSBajajIBSurvaseSASinghalRSKennedyJFMeningococcal polysaccharide vaccines: A reviewCarbohydr Polym2009754553565
   Web of Science ®Google Scholar
• GirardMPPreziosiMPAguadoMTKienyMPA review of vaccine research and development: Meningococcal diseaseVaccine200624224692470016621189
   PubMed Web of Science ®Google Scholar
• PaceDPollardAJMessonierNEQuadrivalent meningococcal conjugate vaccinesVaccine200927Suppl 2B30B4119477560
   PubMed Web of Science ®Google Scholar
• PatelMLeeCKPolysaccharide vaccines for preventing serogroup A meningococcal meningitisCochrane Database Syst Rev20051CD00109315674874
   PubMed Web of Science ®Google Scholar
• CroxtallJDDhillonSMeningococcal quadrivalent (serogroups A, C, W135 and Y) tetanus toxoid conjugate vaccine (Nimenrix™)Drugs201272182407243023231026
   PubMed Web of Science ®Google Scholar
• ShaoPLChangLYHsiehSMSafety and immunogenicity of a tetravalent polysaccharide vaccine against meningococcal diseaseJ Formos Med Assoc2009108753954719586827
   PubMed Web of Science ®Google Scholar
• StephensDSConquering the meningococcusFEMS Microbiol Rev200731131417233633
   PubMed Web of Science ®Google Scholar
• DbaiboGEl-AyoubiNGhanemSImmunogenicity and safety of a quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) administered to adults aged 56 Years and older: results of an open-label, randomized, controlled trialDrugs Aging201330530931923494214
   PubMed Web of Science ®Google Scholar
• PoolmanJBorrowRHyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccinesExpert Rev Vaccines201110330732221434799
   PubMed Web of Science ®Google Scholar
• No authors listedMeningococcal vaccines: WHO position paper, Nov 2011Wkly Epidemiol Rec20118647521539 English, French22128384
   PubMedGoogle Scholar
• SowSOOkokoBJDialloAImmunogenicity and safety of a meningococcal A conjugate vaccine in AfricansN Engl J Med2011364242293230421675889
   PubMed Web of Science ®Google Scholar
• Wilder-SmithAMeningococcal disease: Risk for international travellers and vaccine strategiesTravel Med Infect Dis20086418218618571105
   PubMedGoogle Scholar
• GranoffDMReview of meningococcal group B vaccinesClin Infect Dis201050Suppl 2S54S6520144017
   PubMed Web of Science ®Google Scholar
• FinneJLeinonenMMäkeläPHAntigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesisLancet1983283463553576135869
   PubMed Web of Science ®Google Scholar
• KaaijkPvan der EndeALuytjesWRoutine vaccination against MenB: Considerations for implementationHum Vaccin Immunother201310217
   Web of Science ®Google Scholar
• Novartis media releases Novartis receives EU approval for Bexsero^®, first vaccine to prevent the leading cause of life-threatening meningitis across Europe [webpage on the Internet]BaselNovartis International AG2013 Availabe from: http://www.novartis.com/newsroom/media-releases/en/2013/1672036.shtmlAccessed November 1, 2013
   Google Scholar
• A new MenB (meningococcal B) vaccine [webpage on the Internet]Belfast, Bristol, Dublin, EdinburghMeningitis Research Foundation2013 Available from: http://www.meningitis.org/menb-vaccineAccessed November 1, 2013
   Google Scholar
• AgencyEMBexsero. European public assessment report. Meningococcal group B vaccine (rDNA, component, adsorbed) [webpage on the Internet] Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002333/WC500137857.pdfAccessed November 1, 2013
   Google Scholar
• RoderickMFinnAAdvances towards the prevention of meningococcal B disease: A multidimensional storyJ Infect201468Suppl 1S76S8224139188
   PubMed Web of Science ®Google Scholar
• Novartis International AGBexsero Fact sheetBaselNovartis International AG Available from: http://www.novartisvaccines.com/downloads/meningococcal-disease/Bexsero_Fact_Sheet.pdfAccessed November 1, 2013
   Google Scholar
• ReisingerKSBaxterRBlockSLShahJBedellLDullPMQuadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, MenactraClin Vaccine Immunol200916121810181519812260
   PubMed Web of Science ®Google Scholar
• MenAfriCar ConsortiumAliOAseffaAMeningococcal carriage in the African meningitis beltTrop Med Int Health201318896897823682910
   PubMed Web of Science ®Google Scholar
• FraschCEPreziosiMPLaForceFMDevelopment of a group A meningococcal conjugate vaccine, MenAfriVac(TM)Hum Vaccin Immunother20128671572422495119
   PubMed Web of Science ®Google Scholar
• TrotterCLYaroSNjanpop-LafourcadeBMSeroprevalence of bactericidal, specific IgG antibodies and incidence of meningitis due to group A Neisseria meningitidis by age in Burkina Faso 2008PloS One201382e5548623457471
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC)Serogroup A meningococcal conjugate vaccine coverage after the first national mass immunization campaign-Burkina Faso, 2011MMWR Morb Mortal Wkly Rep201261501022102423254256
   PubMedGoogle Scholar
• NovakRTKambouJLDiomandéFVSerogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance dataLancet Infect Dis2012121075776422818241
   PubMed Web of Science ®Google Scholar
• TrotterCLRamsayMEGraySFoxAKaczmarskiENo evidence for capsule replacement following mass immunisation with meningococcal serogroup C conjugate vaccines in England and WalesLancet Infect Dis200661061661717008169
   PubMed Web of Science ®Google Scholar
• BilukhaOMessonnierNFischerMUse of meningococcal vaccines in the United StatesPediatr Infect Dis J200726537137617468644
   PubMed Web of Science ®Google Scholar
• BorrowRAbadRTrotterCvan der KlisFRMVazquezJAEffectiveness of meningococcal serogroup C vaccine programmesVaccine201331414477448623933336
   PubMed Web of Science ®Google Scholar
• Menitorix – Summary of Product Characteristics [webpage on the Internet]UxbridgeGlaxoSmithKline UK2005 [updated October 10, 2013]. Available from: http://www.medicines.org.uk/emc/medicine/17189/SPC/Accessed on October 29, 2013
   Google Scholar
• GlaxoSmithKlineMENHIBRIX (Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine)BrentfordGlaxoSmithKline plc2012 Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM308577.pdfAccessed on October 29, 2013
   Google Scholar
• CramerJPWilder-SmithAMeningococcal disease in travelers: update on vaccine optionsCurr Opin Infect Dis201225550751722907278
   PubMed Web of Science ®Google Scholar
• PinaLMBassilyEMachmerAHouVReinhardtASafety and immunogenicity of a quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine in infants and toddlers: three multicenter phase III studiesPediatr Infect Dis J201231111173118322814965
   PubMed Web of Science ®Google Scholar
• Committee on Infectious DiseasesMeningococcal conjugate vaccines policy update: booster dose recommendationsPediatrics201112861213121822123893
   PubMed Web of Science ®Google Scholar
• MacneilJRCohnACZellEREarly estimate of the effectiveness of quadrivalent meningococcal conjugate vaccinePediatr Infect Dis J201130645145521206392
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC)Update: Guillain-Barre syndrome among recipients of Menactra meningococcal conjugate vaccine – United States, Jun 2005–Sep 2006MMWR Morb Mortal Wkly Rep200655411120112417060898
   PubMedGoogle Scholar
• VelentgasPAmatoAABohnRLRisk of Guillain-Barre syndrome after meningococcal conjugate vaccinationPharmacoepidemiol Drug Saf201221121350135822807266
   PubMed Web of Science ®Google Scholar
• SmithMJMeningococcal tetravalent conjugate vaccineExpert Opin Biol Ther20088121941194618990080
   PubMed Web of Science ®Google Scholar
• GBS and Menactra Meningococcal Vaccine [webpage on the Internet]AtlantaCenters for Disease Control and Prevention (CDC)2009 [last updated October 9, 2009]. Available from: http://www.cdc.gov/vaccinesafety/vaccines/gbsfactsheet.htmlAccessed on October 15, 2013
   Google Scholar
• NovartisAGMENVEO^® [Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine]CambridgeNovartis Vaccines and Diagnostics, Inc.2010 Available at: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProd-ucts/UCM201349.pdfAccessed on October 1, 2013
   Google Scholar
• Novartis International AGFda Expands Age Indication for Menveo^®, First and Only Quadrivalent Meningococcal Vaccine for Infants as Young as 2 Months Of AgeBaselNovartis International AG2013 Available from: http://hugin.info/134323/R/1720709/572916.pdfAccessed October 1, 2013
   Google Scholar
• VaccinesBloodBiologics: Menveo – Approval Letter [webpage on the Internet]Silver SpringUS Food and Drug Administration2013 [last updated September 10, 2013]. Available from: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm363785.htmAccessed August 1, 2013
   Google Scholar
• Toy BrownRACIP Approves 2014 Child/Adolescent Immunization Schedule. Medscape Available from: http://www.medscape.com/viewarticle/813092Accessed October 23, 2013
   Google Scholar
• CooperBDeToraLStoddardJMenveo®): a novel quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135 and YExpert Rev Vaccines2011101213321162617
   PubMed Web of Science ®Google Scholar
• StamboulianDLopardoGLopezPSafety and immunogenicity of an investigational quadrivalent meningococcal CRM(197) conjugate vaccine, MenACWY-CRM, compared with licensed vaccines in adults in Latin AmericaInt J Infect Dis20101410e868e87520655261
   PubMed Web of Science ®Google Scholar
• Nimenrix. European Medicines Agency [webpage on the Internet]LondonEuropean Medicines Agency2012 [last updated June 6, 2016]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002226/human_med_001548.jsp&mid=WC0b01ac058001d124Accessed on November 13, 2013
   Google Scholar
• DbaiboGMacalaladNAplasca-De Los ReyesMRThe immunogenicity and safety of an investigational meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (ACWY-TT) compared with a licensed meningococcal tetravalent polysaccharide vaccine: a randomized, controlled non-inferiority studyHum Vaccin Immunother20128787388022485050
   PubMed Web of Science ®Google Scholar
• FindlowHBorrowRImmunogenicity and safety of a meningococcal serogroup A, C, Y and W glycoconjugate vaccine, ACWY-TTAdv Ther201330543145823712402
   PubMed Web of Science ®Google Scholar
• KnufMKieninger-BaumDHabermehlPA dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young childrenVaccine201028374475319887137
   PubMed Web of Science ®Google Scholar
• KnufMBaineYBiancoVBoutriauDMillerJMAntibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) in toddlers and young childrenHum Vaccin Immunother20128786687222485049
   PubMed Web of Science ®Google Scholar
• KleinNPBaineYBiancoVOne or two doses of quadrivalent meningococcal serogroups a, C, w-135 and y tetanus toxoid conjugate vaccine is immunogenic in 9- to 12-month-old childrenPediatr Infect Dis J201332776076723348814
   PubMed Web of Science ®Google Scholar
• VesikariTForsténABoutriauDBiancoVVan der WielenMMillerJMRandomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlersHum Vaccin Immunother20128121892190323032159
   PubMed Web of Science ®Google Scholar
• VesikariTKarvonenABiancoVVan der WielenMMillerJTetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: An open, randomized controlled trialVaccine201129254274428421443965
   PubMed Web of Science ®Google Scholar
• VesikariTForsténABoutriauDBiancoVVan der WielenMMillerJMA randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in children aged 2–10 yearsHum Vaccin Immunother20128121882189123032168
   PubMed Web of Science ®Google Scholar
• MemishZADbaiboGMontellanoMImmunogenicity of a single dose of tetravalent meningococcal serogroups A, C, W-135, and Y conjugate vaccine administered to 2- to 10-year-olds is noninferior to a licensed-ACWY polysaccharide vaccine with an acceptable safety profilePediatr Infect Dis J2011304e56e6221278617
   PubMed Web of Science ®Google Scholar
• DbaiboGVan der WielenMRedaMThe tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccineInt J Infect Dis2012168e608e61522704725
   PubMed Web of Science ®Google Scholar
• KnufMRomainOKindlerKImmunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2–10-year-old children: results of an open, randomised, controlled studyEur J Pediatr2013172560161223307281
   PubMed Web of Science ®Google Scholar
• OstergaardLLebacqEPoolmanJMaechlerGBoutriauDImmunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15–25 yearsVaccine200927116116818834910
   PubMed Web of Science ®Google Scholar
• BermalNHuangLMDubeyAPSafety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adultsHum Vaccin20117223924721343698
   PubMed Web of Science ®Google Scholar
• Borja-TaboraCMontalbanCMemishZAImmune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled studyBMC Infect Dis20131311623510357
   PubMed Web of Science ®Google Scholar
• ØstergaardLVan der WielenMBiancoVMillerJMPersistence of antibodies for 42 months following vaccination of adolescents with a meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine (MenACWY-TT)Int J Infect Dis2013173e173e17623246368
   PubMed Web of Science ®Google Scholar
• BaxterRBaineYEnsorKBiancoVFriedlandLRMillerJMImmunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of agePediatr Infect Dis J2011303e41e4821200360
   PubMed Web of Science ®Google Scholar
• LupisanSLimkittikulKSosaNMeningococcal polysaccharide A O-acetylation level does not impact the immunogenicity of the quadrivalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT): results from a randomized, controlled Phase III study in healthy adults aged 18–25 yearsClin Vaccine Immunol201320101499150723885033
   PubMedGoogle Scholar
• McVernonJNolanTRichmondPA randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlersPediatr Infect Dis J2012311e15e2322094636
   PubMed Web of Science ®Google Scholar
• ØstergaardLSilfverdalSABerglundJA tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when co-administered with Twinrix(®) in subjects aged 11–17 years: an open, randomised, controlled trialVaccine201230477478322107850
   PubMed Web of Science ®Google Scholar
• Aplasca-De Los ReyesMRDimaanoEMacalaladNThe investigational meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (ACWY-TT) and the seasonal influenza virus vaccine are immunogenic and well-tolerated when co-administered in adultsHum Vaccin Immunother20128788188722485048
   PubMed Web of Science ®Google Scholar
• Ruiz-PalaciosGMHuangLMLinTYImmunogenicity and safety of a booster dose of the 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine coadministered with the tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers: a randomized trialPediatr Infect Dis J2013321627123076383
   PubMed Web of Science ®Google Scholar
• KnufMPantazi-ChatzikonstantinouAPfletschingerUAn investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix hexa is immunogenic, with an acceptable safety profile in 12–23-month-old childrenVaccine201129254264427321420417
   PubMed Web of Science ®Google Scholar
• Vaccination for Meningococcal disease [webpage on the Internet]LondonPublic Health England2013 [last updated July 12, 2013]. Available from: http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/MeningococcalDisease/GeneralInformation/meninvaccinationfactsheet/Accessed October 1, 2013
   Google Scholar